Advertisement


Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial

2017 ASCO Annual Meeting

Advertisement

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)



Related Videos

Symptom Management
Pain Management

Peter Hoskin, MD, on Spinal Compression: Results From the SCORAD III Trial

Peter Hoskin, MD, of Mount Vernon Cancer Centre, discusses study findings on single-dose radiotherapy compared with multifraction radiotherapy in patients with metastatic spinal canal compression. (Abstract LBA10004)

Breast Cancer

Jame Abraham, MD, on Breast Cancer: Expert Perspective on the MONARCH 2 Trial

Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)

Lung Cancer
Cost of Care

Daniel A. Goldstein, MD, on Pembrolizumab for Lung Cancer: Saving Costs by Adjusting Dosage

Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract 9013)

Kidney Cancer

Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives

Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)

Issues in Oncology

Lee S. Schwartzberg, MD: 2017 Update on ICLIO: Adopting Immunotherapy in the Community Setting

Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.

Advertisement

Advertisement




Advertisement